EGFR and colorectal carcinoma: We analysed 142 samples from 39 KRAS wild‐type fully resected primary tumours of metastatic CRC patients undergoing anti‐EGFR therapy (in first‐, second‐ or third‐line treatment), covering the entire tumour, invasion front and six morphological regions.